公开(公告)号：US20240150402A1

公开(公告)日：2024-05-09

申请号：US18534263

申请日：2023-12-08

Applicant: CytomX Therapeutics, Inc.

Inventor： Stephen James MOORE ,  Margaret Thy Luu NGUYEN ,  Daniel Robert HOSTETTER ,  Olga VASILJEVA

IPC: C07K7/06 ,  A61K47/65 ,  A61K47/68 ,  A61K49/00 ,  C07K7/08 ,  C07K16/00 ,  C07K16/28

CPC classification number: C07K7/06 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6835 ,  A61K47/6889 ,  A61K49/0056 ,  C07K7/08 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/2863 ,  A61K2039/505

Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

公开(公告)号：US11977075B2

公开(公告)日：2024-05-07

申请号：US16219203

申请日：2018-12-13

Applicant: Rappaport Family Institute for Research in the Medical Sciences

Inventor： Yuval Shaked

IPC: G01N33/574 ,  A61P35/00 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28 ,  G01N33/577 ,  G01N33/68 ,  G01N33/74 ,  G06F17/15 ,  G16B5/00 ,  G16B25/10 ,  G16H50/20 ,  G16H50/30 ,  A61K39/00

CPC classification number: G01N33/574 ,  A61P35/00 ,  C07K16/00 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2878 ,  G01N33/577 ,  G01N33/6857 ,  G01N33/74 ,  G06F17/15 ,  G16B5/00 ,  G16B25/10 ,  G16H50/20 ,  G16H50/30 ,  A61K2039/505 ,  G01N2800/52

Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.

公开(公告)号：US11976276B2

公开(公告)日：2024-05-07

申请号：US17520330

申请日：2021-11-05

Applicant: Memo Therapeutics AG

Inventor： Martin Held ,  Christoph Esslinger

IPC: C12N15/10 ,  C07K16/00 ,  C12Q1/6806 ,  C12Q1/686 ,  G01N33/50 ,  G01N33/68

CPC classification number: C12N15/1082 ,  C07K16/00 ,  C07K16/005 ,  C12Q1/6806 ,  C12Q1/686 ,  G01N33/5023 ,  G01N33/5047 ,  G01N33/6845 ,  G01N33/6854 ,  C12Q1/686 ,  C12Q2521/107 ,  C12Q2563/149 ,  C12Q2563/159 ,  C12Q1/6806 ,  C12Q2521/107 ,  C12Q2563/149 ,  C12Q2563/159

Abstract: The present invention is related to a method for recovering two or more genes, or gene products, or cDNAs, encoding for an immunoreceptor having two or more subunits, which two or more genes, or gene products, are comprised in a given source cell. The invention is further related to a method of creating a library of expressor cells, in which library each cell is capable of expressing two or more genes, or gene products, encoding for the subunits of the immunoreceptor. The invention is further related to a method of screening a library of expressor cells as created according to the above method, for one cell that expresses an immunoreceptor that has specificity for a given target molecule.

公开(公告)号：US11975028B2

公开(公告)日：2024-05-07

申请号：US17819219

申请日：2022-08-11

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Ian Frank ,  Michael T. Lotze

IPC: A61K35/17 ,  A01N1/02 ,  A61P35/00 ,  C07K14/725 ,  C07K16/00 ,  C12N5/0783 ,  C12N15/85 ,  G01N33/50

CPC classification number: A61K35/17 ,  A01N1/0284 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/00 ,  C12N5/0636 ,  C12N15/85 ,  G01N33/5005 ,  C07K2317/24 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/04 ,  C12N2501/2302 ,  C12N2502/11 ,  C12N2502/1121 ,  C12N2502/99

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

公开(公告)号：US11974553B2

公开(公告)日：2024-05-07

申请号：US16017221

申请日：2018-06-25

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Frederick W. Alt ,  Hwei-Ling Cheng ,  Ming Tian

IPC: A01K67/0278 ,  A01K67/0271 ,  C07K16/00 ,  C07K16/10 ,  C12N15/85

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  C07K16/00 ,  C07K16/1045 ,  C12N15/8509 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518 ,  C12N2015/8527 ,  C12N2800/30

Abstract: Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.

公开(公告)号：US11971409B2

公开(公告)日：2024-04-30

申请号：US16892642

申请日：2020-06-04

Applicant: Berkeley Lights, Inc.

Inventor： Kevin T. Chapman ,  Mark P. White ,  Xiaohua Wang ,  Minha Park ,  Guido K. Stadler ,  Randall D. Lowe, Jr. ,  Xiao Guan Radstrom ,  Jason M. McEwen ,  Gang F. Wang ,  George L. Fox ,  Peggy A. Radel

IPC: B01L3/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/543 ,  G01N33/569 ,  G01N33/574

CPC classification number: G01N33/574 ,  B01L3/502761 ,  C07K16/00 ,  C07K16/2887 ,  C07K16/30 ,  C12Q1/6886 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/54366 ,  G01N33/56972 ,  B01L2200/0647 ,  G01N2800/7028

Abstract: A method of preparing an antibody therapeutic is provided comprising: (a) providing a dissociated cell sample from at least one solid tumor sample obtained from a patient; (b) loading the dissociated cell sample into a microfluidic device having a flow region and at least one isolation region fluidically connected to the flow region; (c) moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and (d) using the microfluidic device to identify at least one B cell that produces antibodies capable of binding to cancer cells. The cancer cells can be the patient's own cancer cells. Also provided are methods of treating patients, methods of labeling or detecting cancer, engineered T or NK cells comprising antibodies or fragments thereof, and engineered antibody constructs.

公开(公告)号：US11970522B2

公开(公告)日：2024-04-30

申请号：US17006219

申请日：2020-08-28

Applicant: The University of British Columbia

Inventor： Neil R. Cashman ,  Steven S. Plotkin

IPC: C07K7/00 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K38/17 ,  A61K39/00 ,  A61K47/64 ,  A61K51/10 ,  A61P25/28 ,  C07K5/113 ,  C07K5/117 ,  C07K7/64 ,  C07K14/00 ,  C07K14/47 ,  C07K16/18 ,  G01N33/68 ,  A61K38/05 ,  A61K38/07 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69 ,  A61K49/18 ,  A61K51/08 ,  A61L27/22 ,  A61L27/34 ,  A61L29/08 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/103 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K16/00 ,  G01N33/50

CPC classification number: C07K14/4711 ,  A61K39/0008 ,  A61K47/643 ,  A61K47/646 ,  A61K51/1018 ,  A61P25/28 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/64 ,  C07K16/18 ,  G01N33/6896 ,  A61K38/00 ,  A61K38/05 ,  A61K38/07 ,  A61K38/08 ,  A61K38/12 ,  A61K39/00 ,  A61K39/0007 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6081 ,  A61K45/05 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6921 ,  A61K49/1818 ,  A61K51/088 ,  A61K51/10 ,  A61K2300/00 ,  A61L27/227 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/101 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  C07K16/00 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/387

Abstract: The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

公开(公告)号：US20240131193A1

公开(公告)日：2024-04-25

申请号：US18161598

申请日：2023-01-30

Applicant: Modema TX, Inc.

Inventor： Antonin DE FOUGEROLLES ,  Justin GUILD

IPC: A61K48/00 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/21 ,  A61K38/45 ,  A61K38/48 ,  A61K47/54 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/47 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/54 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/00 ,  C12N9/02 ,  C12N9/10 ,  C12N9/12 ,  C12N9/16 ,  C12N9/24 ,  C12N9/42 ,  C12N9/64 ,  C12N9/68 ,  C12N9/88 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00

CPC classification number: A61K48/0066 ,  A61K9/1271 ,  A61K9/145 ,  A61K9/5123 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/7115 ,  A61K38/17 ,  A61K38/177 ,  A61K38/1816 ,  A61K38/1891 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/45 ,  A61K38/4846 ,  A61K47/543 ,  A61K48/0033 ,  A61K48/005 ,  A61K48/0075 ,  C07H21/02 ,  C07K14/005 ,  C07K14/435 ,  C07K14/43595 ,  C07K14/47 ,  C07K14/4705 ,  C07K14/4713 ,  C07K14/4723 ,  C07K14/4746 ,  C07K14/475 ,  C07K14/485 ,  C07K14/495 ,  C07K14/505 ,  C07K14/515 ,  C07K14/525 ,  C07K14/535 ,  C07K14/5418 ,  C07K14/56 ,  C07K14/61 ,  C07K14/62 ,  C07K14/705 ,  C07K14/745 ,  C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/40 ,  C12N9/0069 ,  C12N9/0091 ,  C12N9/1051 ,  C12N9/1241 ,  C12N9/16 ,  C12N9/2402 ,  C12N9/2445 ,  C12N9/6435 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/6443 ,  C12N9/6451 ,  C12N9/88 ,  C12N9/93 ,  C12N15/11 ,  C12N15/52 ,  C12N15/85 ,  C12N15/87 ,  C12P13/04 ,  C12P21/00 ,  C12P21/005 ,  C12Y603/02019 ,  A61K38/00 ,  Y02A50/30

Abstract: The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

公开(公告)号：US20240131043A1

公开(公告)日：2024-04-25

申请号：US18482651

申请日：2023-10-06

Applicant: Coddle Creek Capital, LLC

Inventor： Fred Chasalow

IPC: A61K31/665 ,  A61K33/00 ,  A61K47/68 ,  C07K16/00

CPC classification number: A61K31/665 ,  A61K33/00 ,  A61K47/6835 ,  C07K16/00

Abstract: The present disclosure relates to the use of certain steroids for the diagnosis and treatment of necrotizing enterocolitis and pre-eclampsia.

公开(公告)号：US20240124889A1

公开(公告)日：2024-04-18

申请号：US17609170

申请日：2020-05-07

Applicant: Voyager Therapeutics, Inc.

Inventor： Xiao-Qin Ren ,  Jinzhao Hou ,  Steven Paul ,  Kelly Bales

IPC: C12N15/86 ,  A61K48/00 ,  C07K16/00 ,  C12N9/10

CPC classification number: C12N15/86 ,  A61K48/005 ,  C07K16/00 ,  C12N9/104 ,  C12Y203/02 ,  C12N2750/14143

Abstract: The disclosure provides compositions and methods for the Vectored Augmentation of the Destruction, Expression and/or Regulation of proteins, e.g., VA-DER systems and methods.